MedPath

Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training

Not Applicable
Completed
Conditions
Ischemic Heart Disease
Obesity
Interventions
Other: Weight Loss
Other: Interval Training
Registration Number
NCT01724567
Lead Sponsor
Eva Prescott
Brief Summary

The purpose of the study is to make a head-to-head comparison of weight loss and interval training as methods of secondary prevention in overweight patients with ischemic heart disease.

Detailed Description

In western countries 80 % of patients with ischemic heart disease (IHD) are overweight (BMI \> 25). Weight loss using a low energy diet (LED, 800 - 1000 kcal/day) has been shown to induce a considerable weight loss in obese but otherwise healthy patients and to reduce the risk of cardiovascular disease and diabetes in these subjects. Additionally, a British study using a very low energy diet (VLED, 600 kcal/day) to obtain weight loss, has shown that subject with diagnosed type 2 diabetes had their blood glucose normalized after an 8 week VLED. However, the effect of LED has never been examined in overweight patients with IHD.

Several studies have shown that patients with IHD have a beneficial effect of exercise training regarding mortality and reduction in cardiovascular risk factors. A Norwegian group has shown that aerobic interval training results in the biggest increase in maximal oxygen uptake (VO2max). A high VO2max is correlated to decreased mortality in patients with IHD.

In conclusion, weight loss and exercise are known strategies in preventing progression of IHD and development of type 2 diabetes in these patients, however a head-to-head comparison of the two methods has never been made and it is unknown which intervention is the most effective in improving cardiovascular risk profile. Furthermore, several mechanisms behind the known beneficial effect of these interventions are unknown.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Stable Ischemic Heart Disease
  • BMI 28 - 40 kg/m2

Exclusion criteria:

  • Known Diabetes Mellitus
  • Repeated Fasting plasma glucose ≥ 7 mmol/L or Hba1c > 7 %
  • Severe or moderate valve disease
  • Main stem stenosis
  • Severe heart failure, Ejection Fraction < 35 %
  • Physical or mental disability which are expected to prevent completion of intervention
  • Severe Chronic obstructive Pulmonary Disease (COPD) (FEV1 < 50 % of expected) or asthma
  • Active cancer
  • Severe kidney (GFR < 40 ml/hour) or severe liver disease
  • Severe ischemia or arrhythmias during exercise test
    1. or 3. degree atrio-ventricular (AV) block, not protected by pacemaker
  • Organised training more than 2 times a week prior to inclusion
  • Significant weight loss or weight gain (> 5 %)3 month prior to inclusion
  • Not able to comprehend written and oral informed consent
  • Hormone treatment
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Weight LossWeight Loss12 weeks of Low Calorie Diet to obtain a 10 - 15 % weight loss. Followed by 40 weeks on a weight maintenance diet and interval training 2 times a week.
Interval TrainingInterval Training12 weeks of interval training 3 times a week followed by 40 weeks of interval training 2 times a week.
Primary Outcome Measures
NameTimeMethod
Change in Coronary Flow Reserve following the diet or training intervention and a maintenance period0, 12 and 52 weeks

Assessed by a non-invasive echocardiographic Doppler measurement

Secondary Outcome Measures
NameTimeMethod
Change in body composition following the diet or training intervention and a maintenance period0, 12 and 52 weeks

Assessed by anthropometry, dual X-ray absorptiometry (DXA) (lean body mass, percentage adipose tissue) and abdominal MRI (liver fat, muscle fat, subcutaneous fat and visceral fat at the level of L3).

Change in peak oxygen uptake (VO2max) following the diet or training intervention and a maintenance period0, 12 and 52 weeks

Assessed using a bicycle ergometer

Change in blood pressure following the diet or training intervention and a maintenance period0, 12 and 52 weeks
Change in ceramides, diacylglycerol og endocannabinoid (CB)-1 receptors in adipose tissue following the diet or training intervention and a maintenance period0, 12 and 52 weeks
Change in Heart Rate Variability and silent ischemia following the diet or training intervention and a maintenance period0, 12 and 52 weeks

Assessed by Holter Monitoring for 24 - 48 hours

Change in myocardial blood flow following the diet or training intervention and a maintenance period0, 12 and 52 weeks

Assessed by positron emission tomography of the heart

Change in inflammatory markers in urin, blood and adipose tissue following the diet or training intervention and a maintenance period0, 12 and 52 weeks
Change in endothelial function following the diet or training intervention and a maintenance period0, 12 and 52 weeks

Using the Endopat 2000 from Itamar

Change in systolic and diastolic function following the diet or training intervention and a maintenance period0, 12 and 52 weeks

Assessed by echocardiography resting and during physiological and medical stress.

Change in insulin action, beta cell function and incretin secretion following the diet or training intervention and a maintenance period0, 12 and 52 weeks

A Oral Glucose Tolerance Test is performed.

Change in hormones derived from adipose tissue following the diet or training intervention and a maintenance period0, 12 and 52 weeks
Change in oxidized lipids and lipoprotein particle size following the diet or training intervention and a maintenance period0, 12 and 52 weeks
Change in quality of life following the diet or training intervention and a maintenance period0, 12 and 52 weeks

Trial Locations

Locations (1)

Bispebjerg Hospital

🇩🇰

Copenhagen, Denmark

© Copyright 2025. All Rights Reserved by MedPath